Adagrasib mTOR Inhibitor Combination Cancer Treatment
Summary
USPTO published patent application US20260097038A1 by Mirati Therapeutics covering combination therapies using Adagrasib (KRas G12C inhibitor) with mTOR inhibitors for treating KRas G12C mutant cancers. The application discloses methods of treatment, pharmaceutical compositions, and kits comprising therapeutically effective amounts of both inhibitors.
What changed
USPTO published Mirati Therapeutics' patent application covering pharmaceutical compositions combining Adagrasib (a KRas G12C inhibitor) with mTOR inhibitors for treating KRas G12C mutant cancers. The application discloses therapeutic methods, pharmaceutical compositions, and kits comprising therapeutically effective amounts of both inhibitors.\n\nPharmaceutical companies developing KRas G12C combination therapies should monitor this application's prosecution. If granted, the patent would provide Mirati with exclusivity for this specific combination treatment approach, potentially affecting competitors' freedom to operate in this cancer treatment space.
What to do next
- Monitor for patent prosecution updates
- Review claims for freedom-to-operate analysis
- Assess impact on combination therapy development programs
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH
Application US20260097038A1 Kind: A1 Apr 09, 2026
Assignee
MIRATI THERAPEUTICS, INC.
Inventors
Peter Olson, Ruth Wei Aranda, James Gail Christensen, Lars Daniel Engstrom, Jill Hallin
Abstract
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRas G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
CPC Classifications
A61K 31/519 A61K 31/436 A61K 31/4745 A61K 31/5377 A61P 35/00
Filing Date
2025-12-02
Application No.
19406155
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.